CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2019-08-27
Target enrollment:
Participant gender:
Summary
CMAB008 is an infliximab biosimilar candidate. The host cell of Remicade is mouse myeloma
SP2/0 cell, however, the host cell of CMAB008 is CHO (Chinese hamster ovary cell). It seems
that CMAB008 has lower immunogenicity and higher safety, because Remicade comprises more
complex-type and hybrid-type glycans than CMAB008. However, it is not yet known whether
CMAB008 is not inferior to Remicade. This randomized, double-blind trial investigates the
efficacy and safety of CMAB008 for moderately to severely active rheumatoid arthritis,
compared to Remicade.